Literature DB >> 26171558

Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.

Jogender Singh1, Jayant B Udgaonkar1.   

Abstract

Prion diseases, also known as transmissible spongiform encephalopathies, make up a group of fatal neurodegenerative disorders linked with the misfolding and aggregation of the prion protein (PrP). Although it is not yet understood how the misfolding of PrP induces neurodegeneration, it is widely accepted that the formation of misfolded prion protein (termed PrP(Sc)) is both the triggering event in the disease and the main component of the infectious agent responsible for disease transmission. Despite the clear involvement of PrP(Sc) in prion diseases, the exact composition of PrP(Sc) is not yet well-known. Recent studies show that misfolded oligomers of PrP could, however, be responsible for neurotoxicity and/or infectivity in the prion diseases. Hence, understanding the molecular mechanism of formation of the misfolded oligomers of PrP is critical for developing an understanding about the prion diseases and for developing anti-prion therapeutics. This review discusses recent advances in understanding the molecular mechanism of misfolded oligomer formation by PrP and its implications for the development of anti-prion therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26171558     DOI: 10.1021/acs.biochem.5b00605

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Distance-Based Metrics for Comparing Conformational Ensembles of Intrinsically Disordered Proteins.

Authors:  Tamas Lazar; Mainak Guharoy; Wim Vranken; Sarah Rauscher; Shoshana J Wodak; Peter Tompa
Journal:  Biophys J       Date:  2020-05-20       Impact factor: 4.033

2.  Destabilization of polar interactions in the prion protein triggers misfolding and oligomerization.

Authors:  Suhas H Bhate; Jayant B Udgaonkar; Ranabir Das
Journal:  Protein Sci       Date:  2021-09-30       Impact factor: 6.725

3.  Structure of prion β-oligomers as determined by short-distance crosslinking constraint-guided discrete molecular dynamics simulations.

Authors:  Jason J Serpa; Konstantin I Popov; Evgeniy V Petrotchenko; Nikolay V Dokholyan; Christoph H Borchers
Journal:  Proteomics       Date:  2021-09-16       Impact factor: 5.393

4.  Poly-L-histidine inhibits prion propagation in a prion-infected cell line.

Authors:  Ryo Honda; Kei-Ichi Yamaguchi; Abdelazim Elsayed Elhelaly; Mitsuhiko Fuji; Kazuo Kuwata
Journal:  Prion       Date:  2018-08-17       Impact factor: 3.931

5.  Modulation of the extent of structural heterogeneity in α-synuclein fibrils by the small molecule thioflavin T.

Authors:  Harish Kumar; Jogender Singh; Pratibha Kumari; Jayant B Udgaonkar
Journal:  J Biol Chem       Date:  2017-07-31       Impact factor: 5.157

Review 6.  Generating Ensembles of Dynamic Misfolding Proteins.

Authors:  Theodoros K Karamanos; Arnout P Kalverda; Sheena E Radford
Journal:  Front Neurosci       Date:  2022-03-31       Impact factor: 4.677

7.  Cerebral organoids as a new model for prion disease.

Authors:  Bradley R Groveman; Anna Smith; Katie Williams; Cathryn L Haigh
Journal:  PLoS Pathog       Date:  2021-07-21       Impact factor: 6.823

8.  Endpoint Quaking-Induced Conversion: a Sensitive, Specific, and High-Throughput Method for Antemortem Diagnosis of Creutzfeldt-Jacob Disease.

Authors:  Keding Cheng; Robert Vendramelli; Angela Sloan; Brooks Waitt; Lisa Podhorodecki; Debra Godal; J David Knox
Journal:  J Clin Microbiol       Date:  2016-04-13       Impact factor: 5.948

9.  Potential approaches for heterologous prion protein treatment of prion diseases.

Authors:  Davis M Seelig; Patricia A Goodman; Pamela J Skinner
Journal:  Prion       Date:  2016       Impact factor: 3.931

Review 10.  What Is Our Current Understanding of PrPSc-Associated Neurotoxicity and Its Molecular Underpinnings?

Authors:  Daniel Hughes; Mark Halliday
Journal:  Pathogens       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.